clinical factors in the selection of patients for first-line immunotherapy of lung cancer
Published 7 years ago • 163 plays • Length 2:43Download video MP4
Download video MP3
Similar videos
-
2:03
selecting and managing patients for targeted therapies and immunotherapies for lung cancer
-
2:54
considerations for duration and de-escalation of immunotherapy in lung cancer
-
5:02
going beyond pd-l1 testing for lung cancer immunotherapy
-
1:09:47
how to select the right immunotherapy for first-line treatment of advanced nsclc
-
1:05:53
cancer immunotherapy beyond 2020
-
1:10:25
how to select the right immunotherapy for first-line treatment of advanced nsclc
-
21:39
developing effective immune therapies to treat cancer
-
1:00
lung cancer screening for early stage detection
-
3:46
understanding immunotherapy for lung cancer
-
5:09
immunotherapy for lung cancer: general concepts
-
7:31
outcomes of first-line pembrolizumab monotherapy for pd-l1–positive metastatic nsclc
-
1:06:23
immunotherapy in lung cancer: rationale, evidence, and implications for the multidisciplinary team
-
24:18
immunotherapy biomarkers and patient selection
-
1:47
clinical trial designs and ongoing trials in immunotherapy for lung cancer
-
3:52
precision medicine for lung cancer
-
32:05
clinical trials and cancer immunotherapy: accessing promising treatments
-
1:21
dr. socinski on milestone of immunotherapy in lung cancer
-
3:34
repeat biopsy in lung cancer patients with egfr mutation
-
3:51
new clinical trials underway for advanced lung cancer patients